Elevated Polyreactive Immunoglobulin G in Immune-Mediated Liver Injuries With the Need for Immunosuppressive Therapy - PubMed
3 days ago
- #drug-induced liver injury
- #immunosuppressive therapy
- #autoimmune hepatitis
- Elevated polyreactive immunoglobulin G (pIgG) is a novel biomarker for distinguishing autoimmune hepatitis (AIH) from drug-induced liver injury (DILI) and drug-induced autoimmune-like hepatitis (DI-ALH).
- The study found significantly higher pIgG levels in AIH (1.9 nAU) and DI-ALH (1.7 nAU) compared to DILI (1.1 nAU), non-AIH-non-DILI liver disease (1.0 nAU), and healthy controls (0.27 nAU).
- pIgG demonstrated high diagnostic accuracy (AUC 0.818) and was positive in 79% of AIH patients negative for conventional autoantibodies, and in 90% of DI-ALH cases.
- The study suggests pIgG can complement current serologic tests to identify patients needing immunosuppressive treatment.
- Conflicts of interest include patent applications related to diagnostic methods for AIH, with some authors receiving ELISA kits free of charge for other projects.